Profile data is unavailable for this security.
About the company
Takara Bio Inc is a Japan-based company primarily engaged in businesses related to reagents, instruments, contract services and gene therapy. The Company has one business segment. The reagents, instruments and contract services business provides biotechnology-related research reagents, laboratory instruments and contract services to universities, research institutions and corporations, offering products in the fields of molecular and cell biology based on technologies including polymerase chain reaction (PCR), next-generation sequencing, genome editing and stem cells. The Company also promotes its contract development and manufacturing organization (CDMO) business, which includes contract manufacturing of regenerative medicine products and genetic analysis services. The gene therapy business advances the development of gene therapy drugs including genetically modified T-cell therapies and next-generation chimeric antigen receptor (CAR) technologies.
- Revenue in JPY (TTM)44.15bn
- Net income in JPY-7.20bn
- Incorporated2002
- Employees1.78k
- LocationTakara Bio Inc7-4-38, Noji-HigashiKUSATSU-SHI 525-0058JapanJPN
- Phone+81 775656920
- Fax+81 775618007
- Websitehttps://www.takara-bio.co.jp
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnGes Inc | 874.12m | -5.23bn | 23.74bn | 55.00 | -- | 7.59 | -- | 27.16 | -15.21 | -15.21 | 2.46 | 7.91 | 0.1735 | 0.3487 | 8.45 | -- | -103.74 | -49.52 | -189.41 | -59.16 | 36.65 | 31.53 | -597.83 | -3,839.32 | 1.18 | -23.87 | 0.0174 | -- | 35.81 | 85.31 | 81.42 | -- | -29.27 | -- |
| Heartseed Inc | -100.00bn | -100.00bn | 45.49bn | 39.00 | -- | 6.32 | -- | -- | -- | -- | -- | 314.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.15 | -- | 0.00004 | -- | -- | -- | -- | -- | -- | -- |
| Healios KK | 104.00m | -2.22bn | 51.57bn | 65.00 | -- | 9.04 | -- | 495.87 | -25.70 | -25.70 | 0.9661 | 42.25 | 0.0067 | -- | 0.4952 | -- | -14.27 | -23.01 | -18.09 | -30.33 | -109.62 | -- | -2,143.27 | -2,221.73 | -- | -- | 0.5993 | -- | -81.43 | 30.96 | 47.65 | -- | -11.70 | -- |
| Shin Nippon Biomedical Laboratories Ltd | 31.37bn | 3.99bn | 69.90bn | 1.44k | 17.52 | 1.32 | 9.82 | 2.23 | 95.84 | 95.84 | 753.61 | 1,269.67 | 0.2983 | 1.01 | 5.59 | 21,848,400.00 | 3.73 | 9.90 | 5.31 | 14.82 | 51.59 | 52.68 | 12.50 | 23.35 | 0.6308 | -- | 0.4383 | 30.49 | 22.55 | 17.36 | -10.96 | 14.07 | 54.79 | 58.49 |
| 3-D Matrix Ltd | 8.47bn | 6.47m | 73.58bn | 114.00 | -- | 18.45 | 96.11 | 8.69 | -2.67 | -2.67 | 71.61 | 32.90 | 1.25 | 0.9849 | 4.61 | 74,276,300.00 | 0.0958 | -35.52 | 0.1222 | -46.12 | 68.67 | 59.66 | 0.0764 | -55.66 | 2.53 | -- | 0.2619 | -- | 51.11 | 59.47 | -878.94 | -- | -7.64 | -- |
| Takara Bio Inc | 44.15bn | -7.20bn | 114.52bn | 1.78k | -- | 1.13 | -- | 2.59 | -59.79 | -59.79 | 366.64 | 839.16 | 0.3535 | 1.48 | 5.49 | 24,816,750.00 | -5.73 | 8.66 | -6.12 | 9.70 | 53.99 | 63.76 | -16.20 | 17.16 | 3.83 | -4.82 | 0.0898 | 31.40 | 3.53 | 5.44 | -29.59 | -22.88 | 20.46 | 16.27 |
| GNI Group Ltd | 26.84bn | -4.41bn | 143.66bn | 867.00 | -- | 2.86 | -- | 5.35 | -80.69 | -80.69 | 511.58 | 900.92 | 0.3447 | 2.18 | 4.01 | -- | -9.40 | 0.5414 | -11.37 | 0.6475 | 74.49 | 80.97 | -27.26 | 1.28 | 3.79 | -2.99 | 0.0941 | -- | 13.67 | 22.39 | -501.65 | -- | 34.24 | -- |
| SanBio Co Ltd | 0.00 | -3.44bn | 176.04bn | 29.00 | -- | 330.15 | -- | -- | -48.26 | -48.26 | 0.00 | 6.83 | 0.00 | -- | -- | 0.00 | -138.65 | -47.32 | -177.12 | -57.01 | -- | -- | -- | -- | -- | -12.42 | 0.725 | -- | -- | -- | -9.02 | -- | -46.04 | -- |
| Peptidream Inc | 18.52bn | -3.75bn | 203.92bn | 621.00 | -- | 3.93 | -- | 11.01 | -28.99 | -28.99 | 143.24 | 398.78 | 0.2182 | 3.75 | 3.32 | -- | -4.42 | 8.02 | -5.86 | 9.72 | 40.61 | 64.82 | -20.24 | 18.77 | 1.53 | -16.77 | 0.2485 | 0.00 | -60.32 | 9.66 | -124.97 | -- | 24.52 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 05 Feb 2026 | 1.73m | 1.44% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.70m | 1.41% |
| Amova Asset Management Co., Ltd.as of 06 Feb 2026 | 823.60k | 0.68% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 765.99k | 0.64% |
| Daiwa Asset Management Co. Ltd.as of 30 Jan 2026 | 755.30k | 0.63% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 698.00k | 0.58% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Feb 2026 | 367.50k | 0.31% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 332.20k | 0.28% |
| Sompo Asset Management Co. Ltd.as of 15 Jul 2025 | 273.30k | 0.23% |
| Mellon Investments Corp.as of 06 Feb 2026 | 265.70k | 0.22% |
